pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MNKDMANNKIND CORP

$MNKD4.2600-3.07%
Danbury, CT, USupdated 3h ago

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Marketed: 1pre_registration: 1Unknown: 1
1Marketed1pre_registration1Unknown
Marketed
insulin human
Type 1 Diabetes (Juvenile Diabetes)
Insulin receptor
drug
AFREZZA
1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve…
Insulin receptor
pre_registration
FUROSEMIDE
Edema
Solute carrier family 12 member 1

📅 Upcoming

Nov 4, 2026
earnings
$MNKD4.2600-3.07%
in 3mo
MANNKIND CORP earnings
MANNKIND CORP
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosisrecruitingn=210
  • phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosiscompletedn=27
  • phase3ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspensionterminatedn=132
  • phase3Afrezza® INHALE-1 Study in Pediatricscompletedn=319
  • phase4Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetescompletedn=33
  • phase4INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetescompletedn=141
  • phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteersrecruitingn=40
  • phase4Afrezza® Dosing Optimization Studycompletedn=20
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 10, 26BUYCastagna Michael· Chief Executive Officer100,000 sh @ $2.59$259K↗
routine RSU / option mechanics (6)
  • Apr 22, 26tax coverPrentiss Christopher B · Chief Financial Officer12,267 sh
  • Mar 23, 26grantPrentiss Christopher B · Chief Financial Officer217,000 sh
  • Mar 23, 26grantCastagna Michael · Chief Executive Officer796,000 sh
  • Mar 23, 26grantCastagna Michael · Chief Executive Officer782,000 sh
  • Mar 23, 26grantSingh Sanjay R · EVP Technical Operations221,000 sh
  • Mar 23, 26grantSingh Sanjay R · EVP Technical Operations217,000 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
No open roles indexed yet — view MANNKIND CORP jobs →

News

no news has mentioned this company yet
identifiers
ticker
$MNKD
SEC CIK
0000899460
country
US
source
sec_tickers
top tags
Type 2 Diabetes1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?